Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea

Journal of Managed Care Pharmacy

Volumn 16, Issue 1, 2010, Pages 32-45

  Sohn, Hyun Soon ^a   Suh, Dong Churl ^c   Jang, Eunjin ^b   Kwon, Jin Won ^c  

^a Sookmyung Women's University   (South Korea)

^b National Evidence Based Healthcare Collaborating Agency   (South Korea)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTEREMIA; BIRTH; CHILD; CHILDHOOD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SURVEY; HERD IMMUNITY; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; KOREA; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NATIONAL HEALTH SERVICE; NUTRITION; OTITIS MEDIA; PNEUMOCOCCAL MENINGITIS; PRESCHOOL CHILD; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; SEROTYPE; SOCIETY; STREPTOCOCCUS PNEUMONIA; TREATMENT OUTCOME;

EID: 76549109183     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.1.32     Document Type: Article

References (69)

1. Lee HJ, Kim KH, Chun BC, Choi EH. Disease burden of pneumococcal infection and serotypes of Streptococcus pneumoniae in Korean children. 2006. Korean Centers for Disease Control and Prevention.
2. Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination - a review (2002-2006). Vaccine. 2007;25(8):1355-67.
3. Kim SM, Hur JK, Lee KY, et al. Epidemiological study of pneumococcal nasal carriage and serotypes among Korean children. Korean J Pediatr. 2004;47(6):611-16.
4. Sohn YM. Use of vaccine in the era of antimicrobial resistance: need of effective pneumococcal vaccines. Yonsei Med J. 1998;39(6):611-18.
5. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187-95.
6. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Eng J Med. 2001;344(6):403-09.
7. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810-15.
8. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22(1):10-16.
9. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362(9381):355-61.
10. Kilpi T, Ahman H, Jokinen J, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis. 2003;37(9)1155-64.
11. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54(36):893-97. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5436al.htm. Accessed December 9, 2009.
12. Lee HJ, Kang JH, Kim KH. Establishment of pneumococcal vaccination guidelines. 2005. Korean Centers for Disease Control and Prevention.
13. WHO position paper. Pneumococcal conjugate vaccine for childhood immunization. Wkly Epidemiol Rec. 2007;82(12):93-104. Available at: http://www.who.int/wer/2007/wer8212.pdf. Accessed December 9, 2009.
14. Kang E, Kim K, Lee S, Hong K. Surveillance for antimicrobial resistance of Streptococcus pneumoniae among children of attending day care centers in Seoul, Korea. Korean J Clin Pathol. 2000;20(2):171-77.
15. Kim KH, Lee JE, Whang IT, et al. Serogroup and antimicrobial resistance of Streptococcus pneumoniae isolated from oropharynx in children attending day care center. Korean J Pediatr Soc. 2002;45(3):346-53.
16. Cho KY, Lee JA, Cho SE, et al. A study of serotyping of Streptococcus pneumoniae by multibead assay. Korean J Pediatr. 2007;50(2):151-56.
17. Choi EH, Kim SH, Eun BW, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis. 2008;14(2):275-81.
18. Pneumococcal conjugate vaccine: cost. Medscape Bus Med. Available at: http://www.medscape.com/viewarticle/410906-4. Accessed December 9, 2009
19. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283(11):1460-68.
20. Korea National Statistical Office. Korean Statistical Information Service. Available at: http://www.kosis.kr. Accessed December 9, 2009.
21. Ess SM, Schaad UB, Gervaix A, Pinosch S, Szucs TD. Cost-effectiveness of a pneumococcal conjugate immunization program for infants in Switzerland. Vaccine. 2003;21(23):3273-81.
22. Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine. 2004;22(9-10):1138-49.
23. Salo H, Sintonen H, Nuorti JP, et al. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand J Infect Dis. 2005;37(11-12):821-32.
24. Kim JS, Jang YT, Kim JD, et al. Incidence of Haemophilus influenzae type b and other invasive disease in South Korean children. Vaccine. 2004;22(29-30):3952-62.
25. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infection in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285(13):1729-35.
26. Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J. 1993;12(5):389-94.
27. Koomen I, Grobbee DE, Roord JJ, Donders R, Jennekens-Schinkel A, van Furth AM. Hearing loss at school age in survivors of bacterial meningitis: assessment, incidence, and prediction. Pediatrics. 2003;112(5):1049-53.
28. Goller Y. Cochlear implantation in children: implications for the primary care provider. J Am Acad Nurse Pract. 2006;18(9):397-408.
29. Kim CS, Kim DK, Suh MW, Oh SH, Chang SO. Clinical outcomes of cochlear reimplantation due to device failure. Clin Exp Otorhinolaryngol. 2008;1(1):10-14.
30. Mattila PS. Adenoidectomy and tympanostomy tubes in the management of otitis media. Curr Allergy Asthma Rep. 2006;6(4):321-26.
31. Palmu AA, Verho J, Jokinen J, Karma P, Kilpi TM. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube replacement in children. Pediatr Infect Dis J. 2004;23(8):732-38.
32. Lee YJ, Lee SJ, Park HJ, et al. A clinical study of child bacterial meningitis in Daejeon and Chungcheong area: 2001-2005. Korean J Pediatr. 2007;50(2):156-62.
33. Ahn JH, Lee JY, Kim Y, Kim YI, Shim HJ, Lee KS. Analysis of necessity and adequateness of hearing rehabilitations in hearing impaired persons. Korean J Otolaryngol. 2007;50(3):198-202.
34. Park DC, Choi IS, Heo JH, Lee KW. Acute bacterial meningitis: causative organisms, clinical characteristics and prognosis. J Korean Neurol Assoc. 2000;18(5):556-61.
35. Kim HT, Jang HO, Moon JS, et al. Etiology of community-acquired bacteremia in healthy children. Korean J Pediatr. 2005;48(7):716-22.
36. Choi EH, Lee HJ. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis. 1998;26(6):1346-54.
37. Health Insurance Review & Assessment Service Agency. National Health Insurance Statistical Yearbook. Seoul, South Korea: HIRA; 2006.
38. Lee SO, Woo JH. Epidemiology and etiology of community-acquired pneumonia. J Korean Med Assoc. 2007;50(10):860-67.
39. Jung DS, Kim HS, Park CW, Oh SH. The causative organisms of otitis media accompanying otorrhea in children and their antimicrobial susceptibility. Korean J Pediatr Infect Dis. 2000;7(2):233-39.
40. Lee YJ, Lee WS, Kim KS, Kim KB. Prognosis of bacterial meningitis based on cerebrospinal fluid culture. J Korean Pediatr Soc. 1998;41(5):614-21.
41. Choi EH. Direct and indirect effects of pneumococcal protein conjugate vaccine. J Korean Med Assoc. 2008;51(2):119-26.
42. Lee JA, Kim NH, Park KW, et al. Serotypes and penicillin susceptibility of Streptococcus pneumoniae isolated from clinical specimens and healthy carriers of Korean children. J Korean Pediatr Soc. 2003;46(9):846-53.
43. Choi KM, Yeon SI, Shin JS, Yong DE, Lee KW, Kim DS. Serotype and antimicrobial susceptibility of Streptococcus pneumoniae. Inject Chemother. 2006;38(4):179-85.
44. Korea Center for Disease Control and Prevention. Vaccine information. Available at: http://cdc.go.kr/kcdchome/jsp/home/health/vac/HEALVAC0001Detail. jsp?menuid=100182&contentid=4020&boardid=null&appid= kcdchome&pageNum=3&sub=4&rtabinx=2&q-had01=A&q-had02= 2009&loadType=null&boardseq=null&q-s-l=&q-s-2=&q-s-3=. Accessed December 9, 2009.
45. Kayhty H, Ahman H, Eriksson K, Sorberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J. 2005;24(2)108-14.
46. Esposito S, Pugni L, Bosis S, et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine. 2005;23(14):1703-08.
47. Belgian Health Care Knowledge Centre. Effects and costs of pneumococcal conjugate vaccination of Belgian childrens. KCE Reports Vol. 33C. 2006. Available at: http://kce.fgov.be/index-en.aspx?SGREF=5223&CREF=8069. Accessed December 9, 2009.
48. Kim NH, Lee J, Lee SJ, et al. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar) in Korean infants: differences that are found in Asian children. Vaccine. 2007:25(45);7858-65.
49. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495-502.
50. De Graeve D, Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics. 2004;22(11):719-40.
51. Eskola J, Anttila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J. 1999;18(6):543-51.
52. ezday. Immunization costs. Available at: http://www.ezday.co.kr/bbs/view- board.html?q-id-info=370&q-sq-board=527400. Accessed December 9, 2009.
53. Ministry of Health and Welfare. National Health Insurance Reimbursement Price List. Seoul, South Korea: Korean Medical Association; 2006.
54. Ministry of Health and Welfare. The third Korea National Health and Nutrition Examination Survey. Seoul, South Korea: Ministry of Health and Welfare; 2005.
55. Park SE, Lee H, Lim SY, Kim KY. Immunogenicity of 7-valent pneumococcal conjugate vaccine related to booster immunization in Korean children. Korean J Pediatr. 2008;51(6):622-28.
56. Korea Pharmaceutical Traders Association. Yearbook of Imported Pharmaceutical Goods. Seoul, South Korea: Korea Pharmaceutical Traders Association; 2006.
57. Briggs A, Sculpher M, Claxton K. Further development in decision analytic models for economic evaluation. In: Briggs A, Claxton K Sculpher M, (eds). Decision Modelling for Health Economic Evaluation. New York: Oxford University Press; 2006:45-76.
58. Bos JM, Rümke H, Weite R, Postma MJ. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther. 2003;25(10):2614-30.
59. Shin S, Shin YJ, Ki M. Cost-benefit analysis of Haemophilus influenza type B immunization in Korea. J Korean Med Sci. 2008;23(2):176-84.
60. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31-32):4203- 14.
61. De Wals P, Petit G, Erickson LJ, et al. Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada. Vaccine. 2003;21(25-26):3757-64.
62. Ray GT, Pelton SI, Klugman KP, et al. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine. 2009;27(47):6483-94.
63. Hubben GA, Bos JM, Glynn DM, et al. Enhanced decision support for policy makers using a web interface to health-economic models - illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine. 2007;25(18):3669-78.
64. Dagan R, Sikuler-Cohen M, Zamir O, et al. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotics use in day-care center attendees. Pediatr Inject Dis J. 2001(10);20:951-58.
65. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by non-vaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174-82.
66. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295(14):1668-74.
67. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-46. Available at: http://content.nejm.org/ cgi/reprint/348/18/1737.pdf. Accessed December 9, 2009.
68. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043-51. Available at: http://jama.ama-assn.org/cgi/reprint/294/16/2043. Accessed December 9, 2009.
69. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb Mortality Wkly Rep. 2008;57(6):144-48. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5706a2.htm. Accessed December 9, 2009.